eNeura, maker of the sTMS mini and SAVI medical devices, recently filed for bankruptcy. This means the company may no longer manufacture and support the device, which is a big disappointment to patients with migraine who found relief with eNeura’s devices.
All of us who have migraine know that losing a treatment option can be devastating, as we have to search for new ways to manage our pain and other symptoms. If you currently use the Spring TMS, sTMS mini or SAVI to treat migraine, or if you’ve been searching for an effective drug-free migraine treatment, you should consider trying CEFALY DUAL.
CEFALY vs. sTMS mini/SAVI
Both CEFALY DUAL and the SAVI/sTMS mini/Spring TMS devices are non-invasive medical devices used externally for the acute and preventative treatment of migraine. They work differently, however.
Worn on the forehead, CEFALY DUAL sends tiny electrical impulses through a self-adhesive electrode to stimulate and desensitize the trigeminal nerve, reducing the frequency and intensity of migraine attacks. Research has shown that the trigeminal nerve is a primary pathway for migraine pain.
CEFALY DUAL produces a mild electrical pulse that produces a tingling sensation and sometimes has a sedative effect. It can be used during normal daily activities, and side effects have been shown to be minor and fully reversible. The 60-minute ACUTE setting is clinically proven to relieve migraine pain. In one major study, 79% of acute migraine sufferers saw pain relief and 32% of acute migraine sufferers experienced pain freedom with CEFALY.[i]
With compliant daily use, the 20-minute PREVENT setting can reduce the frequency and intensity of migraine symptoms. In a major study, 38.1% of CEFALY users saw at least a 50% reduction in the number of migraine days. In addition, CEFALY users saw a 19% decrease in frequency of migraine attacks and a 37% reduction in acute drug intake at the end of the three month trial. [ii]
The sTMS mini/SAVI device delivers a single pulse of magnetic energy to the back of the head. This creates a brief electrical current in the brain intended to stop or reduce the effects of migraine headaches. According to the manual, it’s intended to be used twice per day — four pulses in a 15-minute session in the morning, and the same in the evening — for migraine prevention. Sessions of three sequential pulses, with 15-minute breaks in between, are used for acute migraine treatment.
Here’s a quick comparison of the two types of devices.
|
CEFALY DUAL |
sTMS mini/SAVI |
|
Uses external trigeminal nerve stimulation (e-TNS) technology |
Uses single-pulse transcranial magnetic stimulation (sTMS) technology |
|
Worn on the forehead |
Used on the back of the head |
|
One 20-minute session daily for migraine prevention |
Two 15-minute sessions daily for migraine prevention |
|
60-minute sessions as needed for migraine pain relief |
Repeated sessions as needed for migraine pain relief |
|
Available without a prescription |
Required a prescription; is no longer available |
Is CEFALY Right for You?
If you, like many people with migraine, wish you had a way to conveniently treat and prevent migraine without medication, then you may want to try CEFALY DUAL.
Now available without a prescription in the U.S., CEFALY DUAL is indicated to be used for:
- The acute treatment of migraine with or without aura in patients 18 years of age or older.
- The preventative treatment of episodic migraine in patients 18 years of age or older.
CEFALY DUAL is for patients diagnosed by a physician with migraine per the indications for use.
Learn more about how CEFALY works
Try CEFALY Connected risk-free for 90 days
If you have any questions about CEFALY DUAL, please contact us! Our customer support team is ready to answer questions about how CEFALY DUAL works and how to get the best results from your treatment.
Try CEFALY for 90 days, and if you are not satisfied with the product, send it back for a full refund. We’ll even email you a PrePaid FedEx shipping label, so you don’t have to pay for the return shipping.
[i] Chou D. E. et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia. 2019; 39(1): 3-14.
[ii] Jean Schoenen, Bart Vandersmissen, Sandrine Jeangette, Luc Herroelen, Michel Vandenheede, Pascale Gerard, Delphine Magis. PREMICE STUDY Migraine prevention with a supraorbital transcutaneous stimulator. A randomized controlled trial. Neurology Feb 2013, 80 (8) 697-704; DOI: 10.1212/WNL.0b013e3182825055
